Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Johnson and Johnson
Mallinckrodt
AstraZeneca

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Lithium carbonate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for lithium carbonate and what is the scope of patent protection?

Lithium carbonate is the generic ingredient in seven branded drugs marketed by Noven Therap, Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Hikma, Mylan, Usl Pharma, Watson Labs, Solvay, Jds Pharms, Alembic Pharms Ltd, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Mylan Pharms Inc, Unique Pharm Labs, West-ward Pharms Int, Ani Pharms Inc, Bayer Pharms, Pfizer, and Sun Pharm Inds Inc, and is included in thirty-six NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for lithium carbonate. Twenty-five suppliers are listed for this compound.

Drug Prices for lithium carbonate

See drug prices for lithium carbonate

Drug Sales Revenue Trends for lithium carbonate

See drug sales revenues for lithium carbonate

Recent Clinical Trials for lithium carbonate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
StemCyte, Inc.Phase 2
Amarex Clinical ResearchPhase 2
Ariel GildengersPhase 4

See all lithium carbonate clinical trials

Pharmacology for lithium carbonate
Drug ClassMood Stabilizer
Medical Subject Heading (MeSH) Categories for lithium carbonate
Synonyms for lithium carbonate
10377-37-4 (mono-lithium salt)
12767-19-0
1312765-65-3
2006273-00-1
216964-61-3
2BMD2GNA4V
554-13-2
AC1L1WO8
AC1LANIP
AC1Q1U57
ACMC-209lmw
AKOS015904647
AN-45875
ANGC-554-13-2
ANW-32310
B7705
C07964
Camcolit
Candamide
Carbolite
Carbolith
Carbolithium
Carbolithium IFI
Carbolitium
Carbonic Acid Dilithium Salt
Carbonic acid lithium salt
Carbonic acid lithium salt (Li2CO3)
Carbonic acid, dilithium salt
Carbonic acid, lithium salt
Carbonic acid, lithium salt (1:2)
CCRIS 3153
Ceglution
CHEBI:6504
CHEMBL1200826
Cibalith-e
CLi2O3
CP 15467-61
CP-15,467-61
CP-15467-61
CP-1546761
CTK1G9703
D00801
Dilithium carbonate
Dilithium Carbonate, Dilithium Salt, Carbonic Acid
dilithium trioxidocarbonate
dilithium(1+) ion carbonate
diLithoTab CO3
Dilthium Carbonate
DTXSID1023784
Duralite
EC 209-062-5
EINECS 209-062-5
Eskalite
Eskalith
Eskalith (TN)
Eskalith CR
Eutimin
FT-0627895
GK3300
HSDB 3351
Hypnorex
I14-16784
I494
KS-0000025D
KSC269O0H
L0224
Li2CO3
Limas
Liskonum
Litard
Lithane
Lithea
Lithicarb
Lithinate
Lithionate
Lithium carbonate (2:1)
Lithium carbonate (JP17/USP)
Lithium carbonate (Li2CO3)
Lithium carbonate [USAN:JAN]
Lithium carbonate [USAN:USP:JAN]
Lithium Carbonate Nanoparticles
Lithium carbonate, 98+%, for analysis
Lithium carbonate, 99.999%, (trace metal basis), extra pure
Lithium carbonate, 99%, pure
Lithium carbonate, 99+%, ACS reagent
LITHIUM CARBONATE, ACS
Lithium carbonicum
Lithium Phasal
Lithium QD
Lithium, Reference Standard Solution
Lithiumcarbonat
Lithizine
Litho-Carb
Lithobid
Lithobid (TN)
Lithobie
Lithonate
Lithotabs
Lithotabs Priadee
Liticar
LS-88061
Manialith
Maniprex
MFCD00011084
Micalith
MolPort-003-927-648
Neurolepsin
NSC-16895
Pfi-lithium
Pfl-Lithium
Phasal
Plenur
Priadel
Quilonorm
Quilonum retard
RL04084
RTR-019539
Teralithe
Teralithe [French]
TR-019539
TRA0065195
UNII-2BMD2GNA4V
XGZVUEUWXADBQD-UHFFFAOYSA-L
Zabuyelite

US Patents and Regulatory Information for lithium carbonate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 076795-001 Nov 22, 2004 DISCN No No   See Pricing   See Pricing   See Pricing
Ani Pharms Inc LITHOBID lithium carbonate TABLET, EXTENDED RELEASE;ORAL 018027-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   See Pricing   See Pricing   See Pricing
Heritage Pharma LITHIUM CARBONATE lithium carbonate TABLET, EXTENDED RELEASE;ORAL 076366-001 Aug 21, 2003 DISCN No No   See Pricing   See Pricing   See Pricing
Hikma LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 017812-001 Approved Prior to Jan 1, 1982 AB RX Yes No   See Pricing   See Pricing   See Pricing
Mylan Pharms Inc LITHIUM CARBONATE lithium carbonate TABLET, EXTENDED RELEASE;ORAL 202288-001 Jun 29, 2012 AB RX No No   See Pricing   See Pricing   See Pricing
Hetero Labs Ltd Iii LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 090702-002 Sep 25, 2009 AB RX No No   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Medtronic
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.